RPL17 and non-small cell lung carcinoma: For NSCLC patients treated with PD-1 inhibitors as opposed to chemotherapy, 5-year overall survival (OS) rates ranged from 13 to 25% [47] in the second line and as high as 32% in the first line, according to multiple studies [37].